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The pregnane X receptor (PXR) is the molecular target for catatoxic
steroids such as pregnenolone 16a-carbonitrile (PCN), which in-
duce cytochrome P450 3A (CYP3A) expression and protect the body
from harmful chemicals. In this study, we demonstrate that PXR is
activated by the toxic bile acid lithocholic acid (LCA) and its 3-keto
metabolite. Furthermore, we show that PXR regulates the expres-
sion of genes involved in the biosynthesis, transport, and metab-
olism of bile acids including cholesterol 7a-hydroxylase (Cyp7a1)
and the Na1-independent organic anion transporter 2 (Oatp2).
Finally, we demonstrate that activation of PXR protects against
severe liver damage induced by LCA. Based on these data, we
propose that PXR serves as a physiological sensor of LCA, and
coordinately regulates gene expression to reduce the concentra-
tions of this toxic bile acid. These findings suggest that PXR
agonists may prove useful in the treatment of human cholestatic
liver disease.
For over 40 years it has been understood that certain steroidsexhibit a protective effect against various types of intoxica-
tion. These ‘‘catatoxic’’ steroids afford protection against harm-
ful chemicals by accelerating their metabolism (1, 2). A com-
prehensive analysis of steroids in the 1970s identified the
synthetic pregnane pregnenolone 16a-carbonitrile (PCN) as a
potent catatoxic agent in rodents. Subsequent studies revealed
that PCN and other catatoxic compounds stimulate the tran-
scription of the CYP3A subfamily of cytochrome P450 monoox-
ygenases, which are abundant in the liver, where they metabolize
a wide variety of xenobiotics and natural compounds including
steroids and bile acids (3, 4).
In 1998, we reported (5) the identification of a mouse orphan
nuclear receptor, termed the pregnane X receptor (PXR;
NR1I2), which is activated by PCN and other catatoxic com-
pounds. We and others (6–10) subsequently cloned and char-
acterized the human, rabbit, and rat orthologs of PXR. The
human ortholog of PXR is alternately referred to as the steroid
and xenobiotic receptor (SXR; ref. 7) or pregnane-activated
receptor (PAR; ref. 6). PXR is activated by the structurally
diverse collection of compounds that are known to induce
CYP3A expression and binds to xenobiotic response elements
present in CYP3A promoters as a heterodimer with the 9-cis
retinoic acid receptor (RXR; NR2B1). Recently, it was shown
that Cyp3A11 expression is not induced by PCN or dexametha-
sone in mice lacking functional PXR (11). Together, these data
establish PXR as a key regulator of CYP3A expression.
Lithocholic acid (LCA) is a hydrophobic secondary bile acid
that is primarily formed in the intestine by the bacterial 7a-
dehydroxylation of chenodeoxycholic acid. Administration of
LCA and its conjugates to rodents is known to cause intrahepatic
cholestasis (12, 13). Cholestasis, functionally defined as a ces-
sation or impairment of bile flow, can cause nutritional imbal-
ance related to malabsorption of lipids and fat-soluble vitamins
and, moreover, irreversible liver damage as a result of the
accumulation of toxins normally excreted in bile (14). In humans,
elevated levels of LCA are found in patients suffering from
chronic cholestatic liver disease (15). The potentially harmful
effects of LCA and other bile acids are attenuated by two hepatic
detoxification pathways, namely hydroxylation and conjugation.
These reactions make the bile acid more hydrophilic and facil-
itate its excretion in the feces or urine. Notably, 6-hydroxylation
of LCA is catalyzed by members of the CYP3A subfamily
(16, 17).
In 1970, Selye (18) showed that PCN prevented the LCA-
induced hepatoxicity and mortality in rodents. Armed with the
knowledge that PXR is the PCN receptor, we have now inves-
tigated the role of PXR in LCA metabolism. Our data suggest
that PXR plays a fundamental role in protecting the body from
toxic bile acids.
Materials and Methods
Generation of a PXR-Deficient Mouse Line. Three genomic clones
containing the mouse PXR locus were isolated by screening a
129ySv genomic BAC library using a cDNA probe derived from
mouse PXR cDNA. An '15-kb KpnI fragment containing the
first coding exon was isolated and sequenced. A replacement-
type targeting vector was constructed as shown in Fig. 1A. An
'8.0-kb SpeI fragment was subcloned into the SpeI site of
pBluescript (Stratagene). This 8.0-kb fragment, representing the
long arm of the targeting vector, was excised by using the NotI
and SalI restriction sites in pBluescript and inserted at the 59 end
of a neomycin (neo) expression cassette that contains the
neomycin phosphotransferase gene under the control of the
phosphoglycerate kinase I (PGK) promoter. A 3-kb fragment
corresponding to the 39-short arm of the targeting vector was
generated by PCR and inserted into the XhoI site downstream
of the neo expression cassette. A copy of the herpes simplex virus
tk gene, also under the control of the PGK promoter, is located
at the 39 end of the short arm of the vector. This targeting
strategy is summarized in Fig. 1 A.
Embryonic Stem (ES) Cell Culture and Southern Blot Analysis. Mouse
R1 ES cells derived from the 129-Sv strain (19) were cultured and
electroporated as described (20). ES cells in which the plasmid
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integrated by homologous recombination with the endogenous
PXR locus were identified by Southern blot analysis of the DNA
prepared from individual ES cell colonies using a probe derived
from intron 2 (Fig. 1 A). The genomic DNA was digested with
BamHI, transferred to positively charged nylon membrane (Hy-
bond N1; Amersham Pharmacia), and probed with a '400-bp
32P-labeled KpnI-NheI. ES cells carrying the correctly targeted
locus were introduced into C57BLy6J blastocysts and the result-
ing chimeric males bred to C57BLy6 females. Offspring were
screened by Southern blot analysis of DNA obtained from tail
biopsies to identify those heterozygous for the mutant PXR
allele. These heterozygous offspring were then intercrossed to
obtain mice homozygous for the PXR mutation and wild-type
littermate controls.
Maintenance and Treatment of PXR2/2 and Control Mouse Popula-
tions. Adult male wild-type (PXR1/1) and PXR-null (PXR2/2)
mice were maintained on standard laboratory chow and were
allowed food and water ad libitum. Mice were treated with PCN
(0.4 mgyg), dexamethasone (0.1 mgyg), sodium phenobarbital
(PB, 0.1 mgyg), or LCA (0.125 mgyg). All inducers were
dissolved in corn oil and injected intraperitoneally either once
(PCN, dexamethasone, and PB) or twice (LCA) a day for 4 days.
Animals were killed 24 h following the final injection. For LCA
and PCN cotreatment, PCN was administered by gavage (0.5
mgyg in corn oil) for 3 days. Subsequently, PCN treatment was
continued for a further 4 days, during which time animals also
received a daily i.p. injection of LCA (0.25 mgykg in corn oil).
Mice were exsanguinated 24 h following the final injection and
serum alanine transaminase (ALT) and sorbitol dehydrogenase
(SDH) levels determined by using standard techniques. Livers
were fixed in neutral-buffered formalin solution Sigma, embed-
ded in paraffin wax, and stained with hematoxylin and eosin.
Differences between SDH and ALT levels in vehicle- and
LCA-treated and PCN- and LCA-treated animals were deter-
mined by using a one-way ANOVA. Significant differences were
determined by using Duncan’s multiple range post hoc test.
RNA Isolation and Northern Blot Analysis. Total RNA was isolated
from liver by using a commercially available reagent (Trizol; Life
Technologies, Grand Island, NY) according to the manufactur-
er’s instructions. Total RNA (10 mg) was resolved on a 1%
agarosey2.2 M formaldehyde denaturing gel and transferred to
Fig. 1. Disruption of the PXR gene in ES cells and mice. (A) Schematic
representation of the PXR locus segment, the targeting vector and the tar-
geted PXR allele. Open boxes indicate exons and labeled boxes indicate the
PGK-tk and PGK-neo cassettes. Selected restriction endonuclease sites are
indicated: B, BamHI; K, KpnI; N, NheI; S, SpeI; and X, XhoI. A novel BamHI site
is introduced into the PXR locus by the homologous recombination event
allowing the targeted locus to be distinguished from the wild-type allele by
Southern analysis of BamHI digested DNA with the indicated probe (shown at
the right). (B) Northern blot analysis of RNA isolated from the livers of
wild-type and PXR2/2 mice by using the probes indicated in the schematic of
the PXR cDNA. Reverse transcription (RT)–PCR was performed using the
primers indicated in the schematic. Amplification of the wild-type and dis-
rupted PXR mRNAs yielded products of 111 bp and 363 bp, respectively. (C)
Total RNA was prepared from the livers of three wild-type and PXR2/2 mice
treated with PCN, PB, dexamethasone, or vehicle alone. RNA samples were
pooled before Northern blot analysis with probes for Cyp3a11. Bands were
quantitated as described in Materials and Methods and represent the mean
obtained from three animals in each treatment group. Values are normalized
to b-actin and are expressed as fold change relative to wild-type mice receiving
vehicle alone.
Fig. 2. PXR represses Cyp7a1 and induces Oatp2 expression in response to
PCN. Total RNA was prepared from the livers of PXR1/1 and PXR2/2 mice
treated with PCN or vehicle alone. RNA from three animals was pooled and
subjected to Northern blot analysis with probes for (A) Cyp7a1, (B) Oatp2, and
b-actin. Quantitation of bands was performed as described in Fig. 1.
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a nylon membrane (Hybond N1; Amersham Pharmacia). Blots
were hybridized with 32P-labeled cDNAs corresponding to
Cyp3a11 (bases 69 to 1609, GenBank accession no. X60452), rat
tyrosine aminotransferase (TAT; bases 95 to 1562, GenBank
accession no. X02741), rat CYP7A1 (bases 235 to 460, GenBank
accession no. J05460), mouse GR (bases 1982 to 2265, GenBank
accession no. M10901), or the 59-untranslated region of the
murine ortholog of rat Oatp2 (C.D.K., unpublished data).
Subsequently, blots were stripped and reprobed with a radiola-
beled b-actin cDNA (CLONTECH). The intensity of signals
was quantitated by using IMAGEQUANT software (Molecular
Dynamics).
Transient Transfection and Scintillation Proximity Binding Assay.
Transient transfection assays and scintillation proximity binding
assays were performed as described (10). Bile acids were pur-
chased from Steraloids (Newport, RI) or Sigma.
Quantitation of LCA in Urine. LCA levels in urine were quantitated
by atmospheric pressure ionization–liquid chromatography mass
spectrometry (API-LCMS). Briefly, an equal volume of mouse
urine and a 5 mgyml methanolic solution of 2,2,4,4-d4-cholic acid
(D4-cholic acid; CDN Isotopes, Quebec, Canada) were com-
bined. Samples were sonicated, centrifuged (3,000 3 g for 10
min), and filtered through a 0.45-mm filter unit before injection
onto the analytical column of an LCMS instrument (Hewlett–
Packard Series 1100 Liquid Chromatograph Mass Selective
Detector). LCA and D4-cholic acid were detected as the molec-
ular ions ([M-H2]) 375 and 311 myz, respectively, in the negative
selected ion monitoring mode of the instrumentation. LCA
concentrations in the study samples were calculated by compar-
ison to standard solutions of LCA containing D4-cholic acid as
internal standard. The significance of differences between mean
values was analyzed by using an unpaired Student’s t test.
Results
We generated mice lacking functional PXR to study the biolog-
ical functions of this orphan receptor. A genomic clone encom-
passing the entire coding region of the murine Pxr gene was
isolated and characterized. We replaced the first coding exon,
which includes the translation start site and the first zinc finger
of the PXR DNA-binding domain (amino acids 1 to 63; ref. 5),
with a neo resistance cassette by using homologous recombina-
tion (Fig. 1 A). As expected, based on the size of this exon,
Northern blot and PCR analysis showed that PXR2/2 mice
expressed a PXR transcript that was '200 bp shorter than the
wild-type transcript (Fig. 1B). Isolation and sequence analysis of
the mutant PXR amplicon revealed that exon 1 was fused to exon
3 in the mutant animal (data not shown). The truncated PXR
transcript was present at reduced levels in the PXR2/2 mice
Fig. 3. Bile acids bind and activate PXR. (A) CV-1 cells were transfected with
expression plasmids for mouse PXR or human PXR and the reporter plasmid
(Cyp3a23)2-tk-CAT, and the cells treated with 100 mM concentrations of the
indicated bile acids: CDCA, chenodeoxycholic acid; CA, cholic acid; DCA,
deoxycholic acid; LCA, lithocholic acid; 3-keto-LCA, 3-keto-lithocholic acid.
PCN and rifampicin (RIF) were used as positive controls for mPXR and hPXR,
respectively, at 10 mM concentration. Cell extracts were subsequently assayed
for CAT activity. Data represent the mean 6 SD of assays performed in
triplicate. Activation of mPXR by LCA is highly statistically significant as
measured by the Student’s t test (P , 0.001). (B) Scintillation proximity
competition binding assays were performed with human PXR ligand binding
domain and 10 nM [3H]SR12813 in the presence of increasing concentrations
of LCA and 3-keto-LCA. A single-point negative control (tauro-b-muricholic
acid, open triangle) is also shown.
Fig. 4. Effects of treating wild-type and PXR2/2 mice with LCA. (A) Wild-type and PXR2/2 mice were fed a diet supplemented with 0.5% LCA for 8 days. Urine
was collected on day 8 of the study and LCA concentrations were determined. Data represent the mean 6 SEM of assays performed on urine from eight different
mice. ND, not detected; *, Statistically significantly difference between wild-type and PXR2/2, P , 0.05. (B) Total RNA was isolated and pooled from the livers
of six wild-type and PXR2/2 mice injected for 4 days with LCA or vehicle alone and subject to Northern blot analysis with probes for Cyp3a11, Oatp2, and b-actin.
(C) Model for PXR as a bile acid sensor. Activation of PXR by LCA and/or LCA metabolites results in repression of Cyp7a1, which blocks bile acid biosynthesis, and
induction of Oatp2 and Cyp3a expression, which promote bile acid uptake and metabolism. The net effect is to prevent the accumulation of bile acids to toxic
levels.











relative to the wild-type transcript in PXR1/1 animals (Fig. 1B).
Because the first zinc finger is essential for DNA binding, we
expect that even if this mRNA is translated from a spurious
initiation site, the protein produced will not be functional. For
simplicity, we will therefore refer to mice homozygous for this
mutation as PXR2/2. As described (11), PXR2/2 mice were
viable, fertile, bred with normal Mendelian distribution, and did
not exhibit any overt phenotypic change. Extensive serum anal-
ysis did not reveal any significant changes in a number of
parameters, including free- and HDL-cholesterol, steroid hor-
mones (progesterone, estradiol, testosterone, and corticoste-
rone), triglycerides, transaminases, albumin, total bilirubin, and
total bile acids (data not shown). As anticipated, PXR was
required for the induction of Cyp3a11 expression by PCN and
dexamethasone (Fig. 1C). Interestingly, basal levels of Cyp3a11
mRNA were increased '4-fold in the PXR2/2 animals (Fig. 1C),
demonstrating an unexpected role for PXR in the repression of
Cyp3a11 basal expression. This effect of PXR ablation on basal
Cyp3a11 expression was not observed in another PXR2/2 mouse
line that was derived independently (11). The basis for this
difference is not known. Notably, the barbiturate PB induced
Cyp3a11 expression in the PXR2/2 mice to the same degree as
in wild-type mice (Fig. 1C), demonstrating that this xenobiotic
can mediate its effects on Cyp3a11 through a PXR-independent
signaling pathway. Because PB can activate the orphan nuclear
receptor CAR (constitutive androstane receptor; NR1I4; refs. 21
and 22), these data support a role for CAR in the regulation of
Cyp3a11 in vivo.
PCN treatment of rats decreases expression of Cyp7a1, which
encodes the enzyme responsible for the first and rate-limiting
step in the metabolism of cholesterol to bile acids (23). We
examined whether PXR has a role in the negative regulation of
Cyp7a1 expression in mice. Northern blot analysis of Cyp7a1
mRNA levels in PCN-treated wild-type mice revealed an '3-
fold decrease in Cyp7a1 expression relative to animals that
received vehicle alone (Fig. 2A). Interestingly, Cyp7a1 expres-
sion in the PXR2/2 mice was dysregulated in two respects: (i)
The basal level of Cyp7a1 expression was decreased '2-fold in
the PXR2/2 animals; (ii) Cyp7a1 expression was refractory to
PCN treatment (Fig. 2 A). These data demonstrate a role for
PXR in the regulation of both basal Cyp7a1 expression and its
repression by PCN. Expression levels of the nuclear receptors
LXRa (NR1H3) and FXR (NR1H4), which stimulate and
repress Cyp7a1 in response to oxysterols and bile acids (24),
respectively, were unchanged in the PXR2/2 mice (data not
shown). Moreover, expression of the orphan nuclear receptor
small heterodimer partner (SHP, NR0B2), which was recently
implicated in bile acid-mediated repression of Cyp7a1 expression
(25, 26), was unchanged (data not shown).
We also examined the effects of PCN on the expression of other
genes involved in the transport and metabolism of bile acids,
including those encoding the Na1-dependent taurocholate cotrans-
porting polypeptide (Ntcp), multidrug resistance-associated protein
3 (Mrp3), and the Na1-independent organic anion transporter 2
(Oatp2). PCN treatment had no effect on Ntcp or Mrp3 expression
(data not shown). However, PCN treatment strongly induced Oatp2
expression in the PXR1/1 mice, but not in the PXR2/2 mice (Fig.
2B). Oatp2 is a basolateral (sinusoidal) transporter that can mediate
hepatocellular uptake of a wide range of amphipathic substrates,
including bile acids and xenobiotics (27, 28). Interestingly, unlike
Cyp3a11, the basal level of Oatp2 expression was not increased in
the PXR2/2 mice (Fig. 2B).
Because Cyp7a1, Oatp2, and members of the CYP3A sub-
family are involved in bile acid synthesis, transport, and metab-
olism (16, 17, 27–30), we examined whether bile acids might
directly regulate PXR activity. CV-1 cells were transfected with
expression plasmids for either mouse PXR or human PXR (8)
and a reporter plasmid containing two copies of the Cyp3a23
PXR response-element upstream of the thymidine kinase (tk)
gene promoter and chloramphenicol acetyl transferase (CAT)
gene (5). Transfected cells were treated with various bile acids
and their taurine or glycine conjugates. Notably, the secondary
bile acid LCA was an efficacious activator of human PXR and
also activated mouse PXR (Fig. 3A). Neither conjugated LCA
nor any of the other conjugated bile acids activated PXR (data
not shown). 3-Keto-LCA is the major metabolite of LCA in rats:
following LCA feeding, 3-keto-LCA concentrations approach
those of LCA (31). 3-Keto-LCA was an efficacious activator of
both the human and mouse PXR (Fig. 3A). LCA and 3-keto-
LCA bound to human PXR in a scintillation proximity binding
assay with half-maximal inhibitory concentrations of 9 mM and
15 mM, respectively (Fig. 3B). Thus, PXR is a low affinity
receptor for a subset of bile acids.
Fig. 5. PXR activation protects against LCA-induced hepatotoxicity. Wild-
type (A, C, and E) and PXR2/2 (B, D, and E) mice were treated with vehicle alone
(A and B), LCA (C and D), or LCA and PCN (E and F). Liver sections were prepared
for histology and stained with hematoxylin and eosin. Areas of severe necrosis
in panels C, D, and E are indicated with arrows. (G) Serum ALT (open bars) and
SDH (closed bars) levels were measured in wild-type and PXR2/2 mice treated
with either LCA and vehicle (Vehicle) or LCA and PCN (PCN). ALT and SDH
values in untreated animals were 28 6 10 unitsyl and 150 6 20 unitsyml,
respectively. Data represent the mean 6 SEM of assays performed with serum
from six different animals. Statistical differences compared with the same
genotype treated with LCA and vehicle: *, P , 0.005; **, P , 0.001.
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LCA is a highly toxic secondary bile acid that causes cho-
lestasis, a pathogenic state characterized by decreased bile flow
and the accumulation of bile constituents in the liver and blood
(13, 32). Notably, LCA concentrations of 5–10 mM have been
reported in the livers of cholestatic patients and in rat models of
biliary cholestasis (33). Because LCA activates PXR at these
concentrations, we examined whether PXR2/2 mice showed
defects in LCA metabolism. LCA feeding resulted in the ap-
pearance of a sticky residue in the cages of the PXR2/2 mice, but
not in the wild-type mice (data not shown). Analysis of the urine
revealed that PXR2/2 mice had markedly elevated levels of LCA
compared with wild-type animals (Fig. 4A). In addition, we
observed that shorter term treatment of wild-type mice with
LCA resulted in a robust induction of hepatic Cyp3a11 and Oatp2
expression, whereas LCA treatment had no effect on the ex-
pression of these genes in PXR2/2 mice (Fig. 4B). These data
demonstrate that PXR can function as a receptor for LCA
andyor LCA metabolites and regulates LCA metabolism in vivo.
We propose that PXR serves as a physiological sensor of LCA
and its metabolites in the liver and coordinately regulates gene
expression so as to reduce their concentration (Fig. 4C). PXR
inhibits Cyp7a expression, which blocks bile acid synthesis. At the
same time, PXR induces expression of Oatp2 and Cyp3a11, which
may promote the transport and metabolism of LCA. Oatp2 is
localized on the basolateral membrane of the hepatocyte and is
involved in the cellular uptake of bile acids (27, 28). Its induction
by PXR would presumably increase uptake of LCA and other bile
acids from sinusoidal blood into the hepatocyte where hydroxyla-
tion by Cyp3a11 or other Cyp3a subfamily members could take
place. These more hydrophilic bile acid metabolites could then be
excreted in the feces or urine. Although members of the CYP3A
subfamily are known to hydroxylate LCA (16, 17, 30), it is important
to note that bile acid metabolism varies considerably across species
with regard to the enzymes involved and the metabolites produced,
and it is yet to be determined whether Cyp3a11 is involved in the
oxidative metabolism of LCA in mice.
A prediction of this model is that PXR activation will protect
the liver against LCA-induced toxicity. To test this prediction,
wild-type and PXR2/2 mice were treated with LCA in either the
presence or absence of the potent PXR ligand PCN. As expected,
treatment of either wild-type or PXR2/2 mice with LCA resulted
in severe liver damage as manifested by the appearance of
necrotic foci and high serum levels of the liver ALT and SDH
(Fig. 4 A, C, and G). Cotreatment with PCN dramatically
reduced the detrimental effects of LCA on the livers of wild-type
mice (Fig. 4 E and G). In marked contrast, cotreatment with
PCN did not reverse the hepatotoxicity of LCA in the PXR2/2
mice (Fig. 4 B, D, F, and G). Thus, PXR activation strongly
protects the livers of mice from the harmful effects of LCA.
Summary and Perspectives
It has been almost 30 years since Hans Selye first showed that
PCN treatment blocks the hepatotoxicity and mortality caused
by LCA treatment in rats (18). In this report, we have used
PXR-null mice to demonstrate that the orphan nuclear receptor
PXR mediates the hepatoprotective effects of PCN against
LCA-induced toxicity. Moreover, we have shown that PXR is
activated by LCA and its 3-keto metabolite and coordinately
regulates genes involved in the biosynthesis, transport, and
metabolism of LCA. Our results indicate that PXR plays a
fundamental role in protecting the liver against pathophysiolog-
ical levels of LCA. PXR thus joins FXR as nuclear receptors that
are activated by bile acids (34–36). Although PXR and FXR are
activated by distinct sets of bile acids, both receptors are
activated by LCA. This raises the interesting possibility that PXR
and FXR cooperate to remove LCA from the body when its
concentrations reach pathophysiological levels.
Several previous reports suggest that our findings may have
implications in the treatment of human cholestatic liver disease.
Notably, urine from patients suffering from cholestasis contains
elevated levels of 6-hydroxylated bile acids (including the LCA
metabolite hyodeoxycholic acid), which are products of CYP3A4
(16, 37). These findings suggest that increased 6-hydroxylation is
a relevant mechanism for reducing the levels of toxic bile acids
in humans. Elevated levels of 6-hydroxylated bile acids are also
observed in the urine of healthy subjects treated with the PXR
ligand rifampicin (38). Interestingly, rifampicin has been used
successfully in the treatment of pruritus associated with intra-
hepatic cholestasis and, in some instances, has been reported to
induce remission of cholestasis (39–41). The molecular basis for
these clinical effects has remained obscure. Based on our data,
we suggest that the anticholestatic effects of rifampicin may be
mediated through PXR, and that potent PXR ligands may be
more efficacious in the treatment of cholestasis, a severe hepatic
disease for which there is no known cure.
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